Current filters:


7926 to 7935 of 96906 results

Worldwide Rx drug sales forecast to grow to $885 billion by 2018


The market for prescription drugs, based on the consensus forecast for the leading 500 pharmaceutical…

GlobalMarkets & MarketingNovartisPharmaceutical

Osiris gets second approval for Prochymal, in New Zealand


USA-based Osiris Therapeutics (Nasdaq: OSIR) has received a second approval to market its first-in-class…

Asia-PacificBiotechnologyImmunologicalsOsiris TherapeuticsProchymalRegulation

Takeda unit posts updated survival data with HL drug candidate Adcetris


USA based Millennium, a wholly owned oncology subsidiary of Takeda Pharmaceutical (TYO: 4502), yesterday…

AdcetrisMillennium PharmaceuticalsOncologyPharmaceuticalResearchTakeda Pharmaceuticals

ERYTECH Pharma gains EU orphan designation for Enhoxy


French late-stage biopharma company ERYTECH Pharma says that the Committee for Orphan Medicinal Products…

BiotechnologyEnhoxyErytech PharmaEuropeRare diseasesRegulation

Fake Avastin reignites "Track-and-Trace" debate, but the clock is ticking


The US Food and Drug Administration announced in February that counterfeit vials of Roche/Genentech's…

AvastinLegalNorth AmericaPharmaceuticalRegulationRoche

The Medicines Company expands into Russian pharmaceutical market


US drugmaker The Medicines Company (Nasdaq: MDCO) is expanding into Russia, through the start of sales…

AngioxCardio-vascularEuropeMarkets & MarketingPharmaceuticalThe Medicines Company

Teva gets rights to BioAlliance's Sitavig in Israel


French drugmaker BioAlliance Pharma (Euronext Paris: BIO) has signed an exclusive license agreement for…

Anti-viralsBioAlliance PharmaLicensingPharmaceuticalRest of the WorldSitavigTeva Pharmaceutical Industries

Teva launches copy version of Difflam in the UK


The UK subsidiary of Israeli generics giant Teva Pharmaceutical Industries (Nadaq: TEVA) has announced…

DifflamEuropeGenericsMarkets & MarketingMeda PharmaceuticalsNeurologicalOroezeTeva Pharmaceutical Industries

Merck & Co's suvorexant improved patients' ability to fall asleep and stay asleep


US drug giant Merck & Co (NYSE: MRK) has announced new data from two pivotal Phase III efficacy trials…

Merck & CoNeurologicalPharmaceuticalResearchsuvorexant

7926 to 7935 of 96906 results

Back to top